Please assess the completion status of the following clinical trial:

Trial Title: A Evaluation of the Safety of Oncocort IV Pegylated Liposomal Dexamethasone Phosphate in Patients With Progressive Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~1. Previously diagnosed symptomatic MM according to International Myeloma Working Group (IMWG) criteria 1.1. Previously treated with at least two therapy lines including at least one proteasome-inhibitor and at least one immunomodulatory drug 1.2. Relapse after or progressive disease under last therapy according to IMWG criteria.~2. At least 18 years old~3. Measurable disease (M-protein and/or free light chains) in serum and/or urine~4. Willing and able to comply the study protocol visits and assessments~5. Willing to use highly effective methods of birth control (see section 7.1.3)~6. Written informed consent prior to study participation~Exclusion Criteria:~1. Types of Multiple Myeloma previously shown to be irresponsive to dexamethasone monotherapy during the last 6 months~2. Plasma cell leukemia~3. Subject with positive hepatitis panel (including hepatitis B surface antigen \[HBsAg\], and / or anti-hepatitis B core antibodies, and / or hepatitis C virus antibody \[anti-HCV\]), and / or a positive HIV antibody screen~4. Severe abnormal organ function function or laboratory results at the time of the Screening Visit: WBC \<3.0 g/L, ANC \<1.5 G/L, PLT \<50 G/L, Sodium \<135 mmol/L or \>150 mmol/L, potassium \<3.5 mmol/L or \>5.5 mmol/L, calcium \<2.0 mmol/L or \> 2.9mmol/L, phosphorus \<0.8 mmol/L, total bilirubin \>1.5x ULN, AP \>2.5x ULN, gammaGT \>3x ULN, ALT \>3x ULN, CK \>2.5x ULN, Creatinine \>2x ULN, fasting glucose \>250 mg/dL, albumin \<3 g/dL, cholesterol \> 300 mg/dL~5. Treatment with oral or injectable (including intra-articular) corticosteroids (CS) within 4 weeks prior to Screening Visit. Inhaled and dermal corticosteroid formulations are allowed~6. Subjects who have received a chemotherapeutic treatment cycle including dexamethasone within 4 weeks prior to the Screening Visit~7. Known sensitivity to any component of the study drug or previous hypersensitivity reaction or other clinically significant reaction to intravenous medications, biologic therapy or IV radiocontrast agents~8. Active infection requiring systemic treatment~9. Planned major surgery during the study period or had undergone major surgery within 30 days prior to the Screening visit~10. Pregnancy or breastfeeding~11. Any clinically significant hepatic, renal, cardiac, pulmonary, gastrointestinal, metabolic or endocrine disturbances, other medical or psychiatric condition, or clinically relevant abnormal values on any investigation, in the opinion of the Investigator, that could make the subject unsuitable for the study, could compromise subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study, including severe neuropathies or other painful conditions that might interfere with pain evaluation~12. Participation in another clinical investigation less than 4 weeks prior to inclusion~13. The subject has a history of any other illness, which, in the opinion of the Investigator, might pose an unacceptable risk by administering study medication.~14. The subject has any current or past medical condition and/or required medication to treat a condition that could affect the evaluation of the study~15. The subject is unwilling or unable to follow the procedures outlined in the protocol~16. The subject is mentally or legally incapacitated~17. Persons who are in a relationship of dependence to the Investigator or the Sponsor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IV Liposomal Dexamethasone (Type: EXPERIMENTAL): IV Liposomal Dexamethasone given 1 to 4 times in total over period of maximally 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).